About 17,600 results
Open links in new tab
  1. Home | Biogen

    Dec 22, 2025 · Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our …

  2. Company | Biogen

    Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our …

  3. Our U.S. Legacy | Biogen

    Jul 29, 2025 · Headquartered in Cambridge, Massachusetts, Biogen is one of the oldest independent American biotechnology companies. We are North Carolina’s largest biotech …

  4. Pipeline | Biogen

    Oct 30, 2025 · Biogen is dedicated to addressing challenging diseases by leveraging cutting-edge science and driving an innovative pipeline of potential breakthrough therapies in neurology, …

  5. Search Jobs | Biogen

    Access and Health Equity Culture & Inclusion Environment The CoLab Reporting & Principles 2024 Corporate Responsibility Report Company Mission and Culture Our U.S. Legacy …

  6. Careers | Biogen

    Everyone at Biogen contributes to our mission to create transformative medicines for people who need them the most. Explore our business areas to discover where you can make an impact …

  7. Investor Relations | Biogen

    Dec 8, 2025 · Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient’s lives and to create value for …

  8. Science & Innovation - Biogen

    The potential to transform the lives of patients is what drives us at Biogen. As a leading global biotechnology company, we work toward those once-in-a-lifetime moments that could become …

  9. Disease Areas - Biogen

    Biogen has pioneered the development of multiple sclerosis treatments for more than 25 years. We continue to innovate to advance MS treatment and improve outcomes for patients.

  10. News | Biogen

    Dec 8, 2025 · Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet …